BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 37703748)

  • 1. N-glycosylation at N57/100/110 affects CD44s localization, function and stability in hepatocellular carcinoma.
    Cheng Q; Hu X; Zhang X; Yang D; Zhao G; Sun L; Jiang M; Yang L; Cai J; Wang B; Zhang M; Han F; Li Y; Nie H
    Eur J Cell Biol; 2023 Dec; 102(4):151360. PubMed ID: 37703748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Standard CD44 modulates YAP1 through a positive feedback loop in hepatocellular carcinoma.
    Fan Z; Xia H; Xu H; Ma J; Zhou S; Hou W; Tang Q; Gong Q; Nie Y; Bi F
    Biomed Pharmacother; 2018 Jul; 103():147-156. PubMed ID: 29649630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tunicamycin inhibits cell proliferation and migration in hepatocellular carcinoma through suppression of CD44s and the ERK1/2 pathway.
    Hou H; Ge C; Sun H; Li H; Li J; Tian H
    Cancer Sci; 2018 Apr; 109(4):1088-1100. PubMed ID: 29377347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD44 standard isoform is involved in maintenance of cancer stem cells of a hepatocellular carcinoma cell line.
    Asai R; Tsuchiya H; Amisaki M; Makimoto K; Takenaga A; Sakabe T; Hoi S; Koyama S; Shiota G
    Cancer Med; 2019 Feb; 8(2):773-782. PubMed ID: 30636370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD44s adhesive function spontaneous and PMA-inducible CD44 cleavage are regulated at post-translational level in cells of melanocytic lineage.
    Gasbarri A; Del Prete F; Girnita L; Martegani MP; Natali PG; Bartolazzi A
    Melanoma Res; 2003 Aug; 13(4):325-37. PubMed ID: 12883358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Relationship between CD44 expression or glycosylation and hepatocellular carcinoma metastasis].
    Chen BL; Guo K; Liu YK
    Zhonghua Gan Zang Bing Za Zhi; 2011 Dec; 19(12):898-903. PubMed ID: 22525501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IMP3 combined with CD44s, a novel predictor for prognosis of patients with hepatocellular carcinoma.
    Hu S; Wu X; Zhou B; Xu Z; Qin J; Lu H; Lv L; Gao Y; Deng L; Yin J; Li G
    J Cancer Res Clin Oncol; 2014 Jun; 140(6):883-93. PubMed ID: 24647926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Siglec-15 promotes the migration of liver cancer cells by repressing lysosomal degradation of CD44.
    Liu W; Ji Z; Wu B; Huang S; Chen Q; Chen X; Wei Y; Jiang J
    FEBS Lett; 2021 Sep; 595(17):2290-2302. PubMed ID: 34328657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of tumor initiation is dependent on CD44s in c-Met⁺ hepatocellular carcinoma.
    Dang H; Steinway SN; Ding W; Rountree CB
    BMC Cancer; 2015 Mar; 15():161. PubMed ID: 25886575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD44s signals the acquisition of the mesenchymal phenotype required for anchorage-independent cell survival in hepatocellular carcinoma.
    Okabe H; Ishimoto T; Mima K; Nakagawa S; Hayashi H; Kuroki H; Imai K; Nitta H; Saito S; Hashimoto D; Chikamoto A; Ishiko T; Watanabe M; Nagano O; Beppu T; Saya H; Baba H
    Br J Cancer; 2014 Feb; 110(4):958-66. PubMed ID: 24300972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protein expression of CD44 (standard and variant isoforms) in hepatocellular carcinoma: relationships with tumor grade, clinicopathologic parameters, p53 expression, and patient survival.
    Endo K; Terada T
    J Hepatol; 2000 Jan; 32(1):78-84. PubMed ID: 10673070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cholesterol inhibits hepatocellular carcinoma invasion and metastasis by promoting CD44 localization in lipid rafts.
    Yang Z; Qin W; Chen Y; Yuan B; Song X; Wang B; Shen F; Fu J; Wang H
    Cancer Lett; 2018 Aug; 429():66-77. PubMed ID: 29746928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The novel interplay between CD44 standard isoform and the caspase-1/IL1B pathway to induce hepatocellular carcinoma progression.
    Li J; Zhang Y; Ruan R; He W; Qian Y
    Cell Death Dis; 2020 Nov; 11(11):961. PubMed ID: 33168816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The regulation of CD44 expression by new tumor suppressor gene Arid2 and the influence of Arid2 on the invasion and metastasis in hepatocellular carcinoma cells].
    Tian L; Duan YJ; Nie LZ; Li Z; Chen Z; Gao QZ; Yang Y; Tang N; Zheng J
    Zhonghua Gan Zang Bing Za Zhi; 2016 Mar; 24(3):196-201. PubMed ID: 27095763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomolecular characterization of CD44-fibrin(ogen) binding: distinct molecular requirements mediate binding of standard and variant isoforms of CD44 to immobilized fibrin(ogen).
    Alves CS; Yakovlev S; Medved L; Konstantopoulos K
    J Biol Chem; 2009 Jan; 284(2):1177-89. PubMed ID: 19004834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD44: structure, function, and association with the malignant process.
    Naor D; Sionov RV; Ish-Shalom D
    Adv Cancer Res; 1997; 71():241-319. PubMed ID: 9111868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD44s Assembles Hyaluronan Coat on Filopodia and Extracellular Vesicles and Induces Tumorigenicity of MKN74 Gastric Carcinoma Cells.
    Härkönen K; Oikari S; Kyykallio H; Capra J; Hakkola S; Ketola K; Thanigai Arasu U; Daaboul G; Malloy A; Oliveira C; Jokelainen O; Sironen R; Hartikainen JM; Rilla K
    Cells; 2019 Mar; 8(3):. PubMed ID: 30909497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ELK3 promotes the migration and invasion of liver cancer stem cells by targeting HIF-1α.
    Lee JH; Hur W; Hong SW; Kim JH; Kim SM; Lee EB; Yoon SK
    Oncol Rep; 2017 Feb; 37(2):813-822. PubMed ID: 27959451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic relevance of miR-137 in patients with hepatocellular carcinoma.
    Sakabe T; Azumi J; Umekita Y; Toriguchi K; Hatano E; Hirooka Y; Shiota G
    Liver Int; 2017 Feb; 37(2):271-279. PubMed ID: 27473646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycoproteogenomics characterizes the CD44 splicing code associated with bladder cancer invasion.
    Gaiteiro C; Soares J; Relvas-Santos M; Peixoto A; Ferreira D; Paulo P; Brandão A; Fernandes E; Azevedo R; Palmeira C; Freitas R; Miranda A; Osório H; Prieto J; Lima L; Silva AMN; Santos LL; Ferreira JA
    Theranostics; 2022; 12(7):3150-3177. PubMed ID: 35547758
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.